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Objective. There is an unmet need for a specific cardiovascular risk (CV) algorithm for rheumatoid arthritis (RA) patients.
Lipoprotein data are often not available in RA cohorts but could be obtained from frozen blood samples. The objective of this
study was to estimate the storage effect on lipoproteins in long-term (>10 years) frozen serum samples. Methods. Data were used
from an inception RA cohort. Multiple serum samples from 152 patients were analyzed for lipoproteins, being frozen for 1–26 years
at −20∘C. Storage effect on lipoproteins was estimated using longitudinal regression analyses and a lipid decay correction factor
was developed. Clinical impact of the storage effect on lipoproteins was assessed by calculating the number of patients reclassified
to another CV risk group according to the SCORE risk calculator after applying the decay correction factor. Results. There was a
significant effect of storage time on total cholesterol (TC) (P < 0.001) and high density lipoprotein cholesterol (HDL-c) levels (P <
0.001), not LDL-c (P = 0.83).The lipid decay correction factor was 0.03mmol/L and 0.024mmol/L per additional year of storage for
TC and HDL-c, respectively. The TC :HDL ratio decreased after correction for storage effect. After correction, only 5% of patients
were reclassified to another CV risk group. Conclusion. A modest storage decay effect on lipoproteins was found that is unlikely to
significantly affect CV risk stratification. Serum samples that have been stored long-term (>10 years) can be used to obtain valid
lipid levels for developing CV risk prediction models in RA cohorts, even without applying a decay correction factor.
1. Introduction
Cardiovascular (CV) risk is increased in patients with
rheumatoid arthritis (RA) [1]. Cardiovascular diseases
account for 50% of all excess mortality in RA patients [1].
RA itself as a chronic inflammatory condition may increase
CV risk. Also, studies have shown that inflammation may
modulate traditional CV risk factors [2, 3]. Atherosclerotic
plaques in the carotid artery appear more severe and
prevalent in RA patients compared to the general population
[4–7]. In comparison to healthy controls and RA patients
in remission, RA patients with active disease seem to have
less stable plaques that are more vulnerable to rupture,
which increases the probability of a CV event. Considering
the increased risk of CV disease, prevention of CV disease
is important. According to international guidelines this
includes adequate risk assessment using a CV risk algorithm.
In the general population, several algorithms for the
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prediction of CV risk are available, such as the systematic
coronary risk evaluation (SCORE) and the Framingham
risk score [9, 10]. It has recently been reported that both
the SCORE and Framingham risk score algorithm provide
suboptimal CV risk estimates in patients with RA [11, 12]. To
improve CV risk assessment in RA patients, disease specific
risk factors may be required such as RA disease activity. Also,
other cardiovascular-related parameters not incorporated in
the present algorithms, such as carotid artery intima-media
index (cIMT), the presence of plaques in these patients,
or certain genetic markers associated with CV risk factors,
might also be taken into consideration [13–17]. There is
an unmet need for development of a RA specific CV risk
calculator.
In order to develop and validate appropriate CV risk
models for patients with RA, it would be advantageous to use
data from existing cohorts with long follow-up. In existing
cohorts of RA patients, lipid levels usually are not determined
at baseline. Long-term storage may lead to degradation of
cholesterol, that is, a lipid decay. Consequently, if lipids were
to be measured in samples that have been stored for longer
periods of time, cholesterol levels could be underestimated.
Furthermore, if these lipid levels were used in CV risk
algorithms, the result may be an underestimation of CV risk.
Within a timeframe of 1-2 years of storage, no change to
moderate decreases in lipid levels have been reported [18–
20], as well an increase of high density lipoprotein cholesterol
(HDL-c) levels [21, 22]. Lipid decay seems to be smaller at
lower temperatures [18–20]. This has led to the hypothesis
that the HDL concentration influences the effect of storage
on lipoproteins [23]. Overall, total cholesterol (TC) and
triglyceride (TG) levels seems to decay less when stored than
HDL-c levels [24, 25]. One study has investigated the effect
of long-term storage on cholesterol levels for up to seven
years of storage. A significant mean decrease of 2.0% per
year storage in TC levels and a nonsignificant average 1.3%
decrease per year storage in HDL-c levels were reported [26].
To our knowledge, the effect of longer storage (10 years) on
serum cholesterol levels has not been investigated. Although
deterioration of cholesterol content in stored serum samples
can be expected, the magnitude of this effect after long
periods of time is unknown. The objective of this study is to
estimate the long time storage decay effect on TC and HDL-c
levels in frozen serum samples of RA patients and to evaluate
the clinical effect of the decay in CV risk models.
2. Methods
2.1. Study Design. Serum samples at baseline and at 1, 2, 3,
5, 7, and 10 years of follow-up from patients included in the
RA inception cohort of the Radboud University Nijmegen
Medical Centre, from 1985 up to 2009 (𝑛 = 640), were
used for measurements of lipoproteins. To test for a period
effect, patients were stratified in five subcohorts according to
year of inclusion in the cohort during 1985–1989, 1990–1994,
1995–1999, 2000–2004, and 2005–2009 (Figure 1). The study
was approved by the Medical Ethical Committee and CMO
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Subcohort 1 inclusion: 1985–1989
Subcohort 2 inclusion: 1990–1994
Subcohort 3 inclusion: 1995–1999
Subcohort 4 inclusion: 2000–2004
Subcohort 5 inclusion: 2005–2009
Figure 1: Storage and blood sampling times for the 5 subcohorts.
Symbols represent the time points of the included selection of stored
serum, during follow-up (baseline and year 1, 2, 3, 5, 7 and 10).
Arnhem Nijmegen and informed consent was acquired from
all participants.
2.2. Patients. Inclusion criteria for the early RA cohort were
fulfillment of the 1987 ACR classification criteria for RA, dis-
ease duration less than one year, and beingDMARD (disease-
modifying antirheumatic drug) na¨ıve. From this cohort, we
selected at random 150 RA patients from the inception cohort
using computer generated random numbers, to obtain 30
samples per subcohort.
2.3. Serum Samples. During follow-up, nonfasting blood
samples were drawn annually by a trained nurse. Approxi-
mately 400mL of serum was stored from each sample and
divided into four separate vials. The samples were initially
stored at −20∘C. In 2008, all samples were transferred to
storage facilities at−80∘C. Blood samples collected from 2008
and thereafter were stored directly at −80∘C. Blood samples
obtained before 2007 were stored in 1.5mL Eppendorf vials
and samples obtained after 2007 were stored using Greiner
“ppCryovials.” Serum samples that were taken at baseline and
during follow-up (at 1, 2, 3, 5, 7, and 10 years) were extracted
from storage in January 2012. Immediately following this
procedure, samples were prepared for cholesterol measure-
ments and transported on dry ice to the laboratory facilities
of Russells Hall Hospital, Dudley, UK.
2.4. Lipid Measurements. TC concentrations were measured
enzymatically by means of the VITROS CHOL slide tech-
nique using the Triton X-100 surfactant, which is based on
methods described previously [27]. HDL-c was measured
using immunoturbidimetry. Low-density-lipoprotein choles-
terol (LDL-c) was calculated using Friedewald’s formula [28].
2.5. Statistical Analysis. The primary outcomes were the
change in TC and HDL-c levels from baseline to after storage
and the secondary outcome was the change in LDL-c level
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Table 1: Patient characteristics.
𝑛 = 152
Subcohorts
1 (𝑛 = 30)
1985–1989
2 (𝑛 = 31)
1990–1994
3 (𝑛 = 30)
1995–1999
4 (𝑛 = 30)
2000–2004
5 (𝑛 = 31)
2005–2009
Agea 51 ± 14.4 50 ± 13.5 52 ± 14.5 58 ± 12.1 59 ± 12.6
Femaleb 16 (53.3) 19 (61.3) 17 (56.7) 25 (83.3) 21 (67.7)
RF positiveb 26 (86.7) 23 (74.2) 25 (83.3) 23 (76.7) 25 (80.6)
DAS28a 5.6 ± 1.2 5.3 ± 1.4 4.8 ± 1.6 4.9 ± 1.0 5.0 ± 1.2
BMIa 26 ± 3.8 27.1 ± 4.6 25.6 ± 3.3 26.2 ± 3.0 26.6 ± 6.8
Smokersb 14 (46.7) 6 (19.4) 10 (33.3) 9 (30.0) 9 (29.0)
Statin useb 0 (0.0) 0 (0.0) 2 (6.7) 2 (6.7) 9 (29.0)
Glucocorticosteroid useb 3 (10.0) 3 (9.7) 5 (16.7) 17 (56.7) 17 (54.8)
Baseline lipoprotein levels
TC (mmol/L)a 4.2 ± 1.2 4.5 ± 1.5 5.4 ± 1.0 5.3 ± 1.2 5.2 ± 1.2
HDL-c (mmol/L)a 0.6 ± 0.2 0.9 ± 0.3 1.0 ± 0.3 1.1 ± 0.2 1.2 ± 0.4
TC :HDL-ca 7.2 ± 1.9 5.5 ± 1.6 5.9 ± 1.4 5.1 ± 1.2 4.5 ± 1.2
Treatment during follow-up
B-DMARDSb 9 (30.0) 13 (41.9) 10 (33.3) 17 (56.7) 3 (9.7)
(i) Abbreviations: RF, rheumatoid factor; DAS28; disease activity index 28 joints, BMI: bodymass index, TC, total cholesterol; HDL-c, high-density-lipoprotein
cholesterol, B-DMARDS; biological disease modifying anti-rheumatic drugs.
(ii) aData presented as mean ± SD, bData presented as 𝑛 (%).
from baseline to after storage. To test for a period effect, a
longitudinal regression analysis was used that corrects for
repeated measurements within patients. Lipid level (TC and
HDL-c) was the dependent variable and follow-up time;
subcohort (1985–1989, 1990–1994, etc.) and an interaction
term between follow-up time and subcohort were the main
independent variables. As the course of cholesterol levels
over follow-up time was nonlinear, a quadratic time term
(time2) was included. To test for a period effect in the course
of cholesterol levels, the interaction between subcohort
and follow-up time was evaluated. Several variables were
considered as potential confounders: age, gender, statin use
at baseline, BMI, smoking, blood pressure, DAS28 score,
rheumatoid factor positivity, and glucocorticosteroid use.
Variableswere considered confounders if their addition to the
model led to a>10% change in one of the subcohort follow-up
time effects.
For the development of a correction factor for the storage
decay effect, linear mixed models were used, with cholesterol
level as the dependent variable, storage time as primary
independent variable, and the same confounders as in the
analyses described previously. Storage time was calculated by
subtracting the baseline date (date the blood samples were
first frozen) from the date of serum analysis. The storage
decay correction factor developed to adjust the TC, HDL-
c, and LDL-c levels was defined as the estimated change in
mmol/L cholesterol (𝛽Chol) per additional unit of storage
time (years) multiplied by the number of storage years
(𝑡) of a particular sample. When added to the measured
cholesterol level (𝛽observed), it gives an estimate of the
“original” cholesterol value (𝑦).The lipid storage decay factor
is therefore 𝑦 = 𝛽observed + (𝛽Chol ∗ 𝑡).
In order to evaluate the clinical effect of the decay in CV
riskmodels, reclassification across CV risk groups before and
after correction was calculated. The SCORE risk algorithm
was used to quantify the 10-year risk ofCVDwith andwithout
correction for the storage decay effect. The CV risk was
calculated with and without correction for the storage decay
effect on lipids for all 1050 patients from the RA inception
cohort. Reclassification of patients across CV risk groups (low
<10%, intermediate 10–20%, and high <20%) was calculated.
If CV risk of a patient exceeds 10%, primary prevention in
the form of lifestyle changes ormedical treatment is indicated
according to European guidelines for CV prevention [29].
3. Results
3.1. Patients. One hundred and fifty two patients were
included, evenly distributed across the 5 subcohorts (Table 1),
with storage times ranging from 1 to 26 years. Samples
from the oldest subcohorts comprised the longest storage
times. Serum samples from seven time points (0, 1, 2, 3,
5, 7, and 10 years) were analyzed if available, yielding a
total of 971 samples. Age, gender, rheumatoid factor (RF)
positivity, disease activity index 28 joints (DAS28), use of
statins, and glucocorticosteroids appeared to show trends
over time (Table 1).
3.2. Differences between Subcohorts. Lipid levels measured
at baseline are presented in Table 1. Lipid levels tended to
be lowest in the subcohorts (Figure 2) that had the longest
storage time and there appeared to be a nonlinear course
of lipid levels during storage time. The unadjusted results
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Figure 2: Lipoprotein levels measured in stored serum samples in the various subcohorts. Total cholesterol (a) and HDL-c (b) are depicted
on the 𝑦-axis. Samples taken at the most recent follow-up moment in time, time point “10” on the 𝑥-axis, have the shortest follow-up time
and samples taken at baseline (time point “0”) have been stored the longest.
(not shown) revealed a significant interaction effect between
subcohort and follow-up time for TC and LDL-c (𝑃 = 0.02
and 𝑃 = 0.01, resp.). Overall, the course of the various
lipoprotein levels over time was not significantly different
between subcohorts after adjustment for confounders (age,
gender, and BMI) with 𝑃 = 0.09, 𝑃 = 0.05, and 𝑃 = 0.18 for
TC, LDL-c, and HDL-c, respectively. Rheumatoid factor and
DAS28 were not confounders after these adjustments.
When looking specifically at the oldest and most recent
cohort (the two extremes in terms of storage time), lipid
levels in the oldest cohort were systematically lower than lipid
levers in the most recent subcohort; a statistically significant
difference for TC and LDL-c (𝑃 = 0.04 and 𝑃 = 0.03) and a
nonsignificant difference for HDL-c (𝑃 = 0.25) were found
after correction for confounders.
3.3. Storage Time. There was a significant decay effect of
storage time on TC and HDL-c levels (𝑃 < 0.001) (Tables
2 and 3). No effect of storage time was found for LDL-c levels
(𝑃 = 0.83, data not shown). For the analysis for TC and LDL-
c, age, gender, BMI, statin use, and glucocorticosteroid use
at baseline were confounders and adjusted for. For HDL-c, a
model with adjustment for age and gender sufficed.
As a significant decay effect was found for TC andHDL-c,
a correction factor was estimated. As storage time increased,
a decrease (95% CI) was observed, −0.03mmol/L (−0.045–
−0.015) for TC and−0.024mmol/L (−0.027–−0.021) forHDL-
c per year of increasing storage time. The decrease in HDL-c
levels was relatively larger (considering the range) than the
decrease in TC levels at same length of storage. The TC/HDL
ratio calculated for the same sample will therefore become
higher as a direct result of increasing storage time and the
disproportionate decay effect on TC and HDL-c. This lipid
decay was estimated to be linear. A lipid decay correction
factor was calculated to be [𝑦 = 𝛽observed + (𝛽Chol ∗ 𝑡)]
0.03mmol/L for TC and 0.024mmol/L for HDL-c. Figure 3
illustrates the differences in the course of unadjusted and
adjusted cholesterol levels.
3.4. Clinical Impact of the Storage Decay Effect on Lipids.
The storage decay effect of lipids during storage affects the
TC :HDL-c ratio. This ratio is used when calculating the
10-year CV risk of individual patients in a clinical setting.
Patients are then categorized as either “low” risk (<10% 10-
year risk of a CV event), “intermediate” risk (10–20% 10-year
risk of a CV event), or “high” risk (>20% 10-year risk of a CV
event). As a result of the storage decay effect, the TC :HDL-
c ratio calculated using the measured lipoprotein levels
decreases as storage time increases. To better approximate the
lipoprotein levels at the time the serum samplewas taken, and
the lipid decay correction factor was estimated. Correction
for the storage decay effect will yield a higher (improved)
TC :HDL ratio which reduces the calculated CV risk. After
applying the storage correction factor, the TC :HDL-c ratio
decreased. Before correction, TC :HDL ratio was classified as
high in 75% of patients, compared to 54% after correction
(not shown). After correction, patients moved to lower CV
risk groups, as the TC :HDL-c ratio decreases after correction
for the storage decay effect (Table 4). Before correction, most
patients were categorized in the “low” CV risk group (<10%)
and 53 patients were reclassified from the intermediate and
high risk groups to this group, totaling 552 patients (an 11%
increase) after correction. The intermediate (10–20%) and
high (>20%) CV risk groups decreased in size by 8% and 11%,
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Table 2: Effect of storage time (years) on TC levels.
Estimate SE 𝑃-value 95% CI
Lower Upper
Constant 3.408 0.389 <0.0001 2.65 4.17
Storage time −0.030 0.008 <0.0001 −0.045 −0.015
Time within patients (follow-up) 0.012 0.003 <0.0001 0.001 0.018
Time2 (follow-up) −0.0001 0.00003 <0.0001 −0.0002 −0.0001
Gender 0.023 0.097 0.810 −0.167 −0.213
Age 0.016 0.004 <0.0001 0.087 0.023
Statin use at baseline 0.888 0.188 <0.0001 0.519 1.256
BMI 0.011 0.011 0.343 −0.011 0.033
Glucocorticosteroid use at baseline 0.239 0.115 0.038 0.013 0.465
(i) SE, standard error; BMI, body mass index; and 95% CI: 95% confidence interval.
(ii) Data are adjusted for age, gender, statin use at baseline, BMI, and glucocorticosteroid use at baseline.
(iii) Time2 is a quadratic term that was included due to the nonlinear course of cholesterol levels over follow-up time, and this variable also represents time
within patients (follow-up time).
Table 3: Effect of storage time (years) on HDL-c levels, adjusted results.
Estimate SE 𝑃value 95% CI
Lower Upper
Constant 1.247 0.056 <0.0001 1.136 1.358
Storage time −0.024 0.002 <0.0001 −0.027 −0.021
Time within patients (follow-up) 0.003 0.001 <0.0001 0.001 0.004
Time within patients2 (follow-up) −0.00003 0.00001 <0.0001 −0.00004 −0.00002
Age 0.003 0.001 0.001 0.001 0.004
Gender −0.074 0.021 0.001 −0.117 −0.031
(i) SE, standard error; 95% CI, 95% confidence interval.
(ii) Data are adjusted for age, gender, and time within patients2.
respectively. Overall, in this cohort of 1050 patients, 53 (5%)
patients changedCV risk groups according to SCORE 10-year
risk predictions for CVD.
4. Discussion
Our study is the first to investigate the suitability of choles-
terol levels obtained in serum samples that have been stored
for more than 10 years and to evaluate if this storage decay
effect is clinically important for CV risk evaluation in RA
patients using available CV risk calculators. We show that
a significant but modest storage decay effect on cholesterol
levels occurs over time.Themagnitude of this effect per addi-
tional year of storage is relatively small. Correcting factors
to adjust for this effect were calculated, 0.03mmol/L for TC
and 0.024mmol/L for HDL-c, per additional year of storage.
Interestingly, the change in TC and HDL-c per additional
year of storage in this cohort is similar, which means that the
impact of this storage decay effect will be greater for HDL-
c, as the range of HDL-c levels is much smaller compared
to TC levels. The decay effect of TC levels reported in this
study is less steep than the decrease in HDL-c. Therefore,
the observed TC :HDL ratio may become increased and
lead to false-higher CV risk predictions. In particular, lipid
measurements in samples that have undergone long-term
storage could be inaccurate, which would eventually lead
to distorted risk predictions if these values were used in a
CV risk model. However, this does not seem to be the case.
Clinical impact of the storage decay effect appears to be
minimal, with only a small number of patients (5%) moving
from groups indicated for primary CV prevention (either
the intermediate or high risk) to the low risk group after
application of a correction factor. Although, on an individual
level, changes in absolute lipid levels may be relevant, these
changes do not appear to significantly affect cardiovascular
risk predictions. Therefore, it may not be necessary to use a
correction factor when samples have been stored under stable
conditions.
Determining whether long-term storage affects the
integrity of lipid samples requires analysis of long-term data.
Ideally one would compare values determined in the past,
directly after acquiring the blood sample (“original” values),
with values determined from stored samples (“observed” val-
ues) within patients. The differences between “original” val-
ues and “observed” values provide an immediate indication
of the storage effect. Several studies have used this approach
but in serum samples that were stored for relatively short
periods of 1-2 years [19, 20, 24, 25]. However, measurements
of lipids directly after blood sampling are not always available
in RA cohorts. This may be due to the fact that the awareness
of the increased risk of CVD gained particular interest long
after the start of RA cohorts. Hence a different approach
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Figure 3: Lipoprotein levels measured over time in the various subcohorts before and after correction with the lipid decay factor. Mean TC
and HLD-c levels are depicted on the 𝑦-axis and follow-up time on the 𝑥-axis.
Table 4: CV risk reclassification.
CV risk Before correction for storage decay
𝑛 (%)




Low (<10%) 499 (48%) 552 (53%) +53 (11%)
Intermediate (10–20%) 178 (17%) 164 (16%) −14 (8%)
High (>20%) 373 (35%) 334 (31%) −39 (11%)
Total 𝑛 (%) 1050 (100%) 1050 (100%) +53 (5%)
(i) CV risk, cardiovascular risk.
(ii) Number of patients reclassified according to the SCORE CV risk categories for the 10-year risk of a CV event; (low; <10%, intermediate; 10–20%, and high;
>20%) before and after correction for storage decay effect on TC and HDL-c.
is required to assess the storage decay effect on lipid levels
in these cohorts. In a study that investigated the effect of
long-term storage (7 years) [26], the group means of lipids
for pairs of serial specimens that were taken at 6- and 12-
month intervals were compared. It was assumed that in the
absence of a storage effect the variation in groupmeanswould
reflect only normal biological variation, which would not
lead to a systematic downward or upward effect in the group
mean cholesterol levels. Subsequently, any observed changes
would reflect the storage effect [26]. However, in a long-
running cohort that includes a lengthy follow-up of more
than 10 years, patients could also be systematically different
between different time-periods. For example, patients that
were included more recently are probably more likely to use
statins at the time the serum samples were taken than patients
that were included 25 years ago. In this cohort, cholesterol
levels from samples that were stored the shortest could
therefore be systematically lower than samples that were
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stored the longest, without involvement of a storage effect.
Such a period effect could lead to biased results. Therefore,
we used a method in which the data were grouped according
to five different time-periods for analysis, to adjust results for
a period effect. Illustratively, statin use at baseline increased
from 0% in the first three subcohorts (1985–1999) to 29%
in the last cohort (2005–2009). The percentage of smokers
decreased from 47% to 29% during that same timeframe.
Overall, these subcohorts did not seem to differ significantly,
excluding period effect as a confounder. Consequently, a
simplified model was developed. The methodology used in
this study can also be applied in other cohorts.
This study has limitations. The storage effect was esti-
mated without knowing “original” values for comparison.
The correction factor was directly derived from the regres-
sion coefficient of storage time. It was assumed that after
correction for repeated measures and for confounders any
observed change is attributable to the storage effect. Biologi-
cal variation of lipid levels within a subject could potentially
contribute to the found decay effect over time. However,
several (𝑛 = 7) measurements per patient were included,
in the total group of 152 patients. Serum samples had been
stored under similar condition, albeit in different storage
facilities. It was considered unlikely that any variation, either
due to biological variation within patients or due to differ-
ing storage circumstances, would contribute to an overall,
systemic trend. It has been previously suggested that such
variability in measured cholesterol levels is unpredictable
and often a wide variation in both directions (±20%) is
reported [30, 31]. In the model that was formulated, the most
important confounders were dealt with, but the existence
of other confounding factors cannot be excluded. Storage
conditions, varying temperatures during storage, andnumber
of times the samples were thawed are all factors that could
have contributed in affecting serum cholesterol levels. As
multiple sets of samples from 152 patients were used, it is
considered unlikely that any of these highly variable factors
contributed significantly to the systemic decay effect that was
found. In addition, modifying the storage temperature from
−20∘C to −80∘C for all serum samples in 2008 is a limitation,
although the vast majority of the samples (1985–2007) were
stored under the same conditions. Storage effects are likely to
be even smaller with lower temperatures.
In conclusion, the results of this study show that modest
decay of lipid levels in serum samples should be expected
during long-term (>10 years) storage. Using the method
proposed here, a correction factor can be formulated to adjust
for this storage decay effect. However as the clinical impact on
CV predictions appears minimal, extensive adjustment may
not be necessary to obtain valid lipid levels. Hence, stored
serum samples, even when stored for long periods of time,
are a valuable source of data. These data can be of particular
importance for studies in RA cohorts involving long-term
outcomes such as cardiovascular disease. In addition, it may
be financially attractive to minimize the analysis period
by performing cholesterol measurements in stored serum
samples all at once at the end of a long-term study with
multiple samples taken over long periods of time. It is
recommended to employ the method presented in this study
in other long-term cohorts.
Abbreviations
CV: Cardiovascular
SCORE: Systematic coronary risk evaluation
TC: Total cholesterol
HDL-c: High density lipoprotein cholesterol
TG: Triglycerids
DMARD: Disease-modifying antirheumatic drug
LDL-c: Low-density lipoprotein cholesterol
RF: Rheumatoid factor
TC :HDL: Total cholesterol : high density lipoprotein
cholesterol ratio.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Funding
This research received no specific grant from any funding
agency in the public, commercial, or not-for-profit sectors.
References
[1] J. A. Avina-Zubieta, J. Thomas, M. Sadatsafavi, A. J. Lehman,
and D. Lacaille, “Risk of incident cardiovascular events in
patients with rheumatoid arthritis: a meta-analysis of observa-
tional studies,” Annals of the Rheumatic Diseases, vol. 71, no. 9,
pp. 1690–1697, 2012.
[2] P. H. Dessein, B. I. Joffe, and S. Singh, “Biomarkers of endothe-
lial dysfunction, cardiovascular risk factors and atherosclerosis
in rheumatoid arthritis,”Arthritis Research&Therapy, vol. 7, no.
3, p. R634, 2005.
[3] P. H. Dessein, A. E. Stanwix, and B. I. Joffe, “Cardiovascular
risk in rheumatoid arthritis versus osteoarthritis: acute phase
response related decreased insulin sensitivity and high-density
lipoprotein cholesterol as well as clustering of metabolic syn-
drome features in rheumatoid arthritis,” Arthritis Research, vol.
4, no. 5, p. R5, 2002.
[4] H. Kobayashi, J. T. Giles, J. F. Polak et al., “Increased prevalence
of carotid artery atherosclerosis in rheumatoid arthritis is
artery-specific,”The Journal of Rheumatology, vol. 37, no. 4, pp.
730–739, 2010.
[5] M.-C. Aubry, H. Maradit-Kremers, M. S. Reinalda, C. S.
Crowson, W. D. Edwards, and S. E. Gabriel, “Differences in
atherosclerotic coronary heart disease between subjects with
andwithout rheumatoid arthritis,”TheJournal of Rheumatology,
vol. 34, no. 5, pp. 937–942, 2007.
[6] C. Gonzalez-Juanatey, J. Llorca, A. Testa, J. Revuelta, C.
Garcia-Porrua, andM. A. Gonzalez-Gay, “Increased prevalence
of severe subclinical atherosclerotic findings in long-term
treated rheumatoid arthritis patients without clinically evident
atherosclerotic disease,” Medicine, vol. 82, no. 6, pp. 407–413,
2003.
[7] G. A. Karpouzas, J. Malpeso, T. Y. Choi et al., “Prevalence,
extent and composition of coronary plaque in patients with
8 BioMed Research International
rheumatoid arthritis without symptoms or prior diagnosis of
coronary artery disease,”Annals of the Rheumatic Diseases, 2013.
[8] A. G. Semb, S. Rollefstad, S. A. Provan et al., “Carotid plaque
characteristics and disease activity in rheumatoid arthritis,”
Journal of Rheumatology, vol. 40, no. 4, pp. 359–368, 2013.
[9] R. M. Conroy, K. Pyo¨ra¨la¨, A. P. Fitzgerald et al., “Estimation
of ten-year risk of fatal cardiovascular disease in Europe: the
SCOREproject,”EuropeanHeart Journal, vol. 24, no. 11, pp. 987–
1003, 2003.
[10] K. M. Anderson, P. W. F. Wilson, P. M. Odell, and W. B.
Kannel, “An updated coronary risk profile. A statement for
health professionals,” Circulation, vol. 83, no. 1, pp. 356–362,
1991.
[11] C. S. Crowson, E. L. Matteson, V. L. Roger, T. M.Therneau, and
S. E. Gabriel, “Usefulness of risk scores to estimate the risk of
cardiovascular disease in patients with rheumatoid arthritis,”
TheAmerican Journal of Cardiology, vol. 110, no. 3, pp. 420–424,
2012.
[12] E. E. A. Arts, C. D. Popa, A. A. den Broeder et al., “Performance
of five current risk algorithms in predicting cardiovascular
events in patients with early rheumatoid arthritis,”Annals of the
Rheumatic Diseases, 2014.
[13] A. Corrales, J. A. Parra, C. Gonza´lez-Juanatey et al., “Car-
diovascular risk stratification in rheumatic diseases: carotid
ultrasound ismore sensitive thanCoronaryArteryCalcification
Score to detect subclinical atherosclerosis in patients with
rheumatoid arthritis,”Annals of the Rheumatic Diseases, vol. 72,
no. 11, pp. 1764–1770, 2013.
[14] A. Corrales, C. Gonza´lez-Juanatey, M. E. Peiro´, R. Blanco,
J. Llorca, and M. A. Gonza´lez-Gay, “Carotid ultrasound is
useful for the cardiovascular risk stratification of patients
with rheumatoid arthritis: results of a population-based study,”
Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 722–727,
2014.
[15] L. Rodr´ıguez-Rodr´ıguez, C. Gonza´lez-Juanatey, R. Palomino-
Morales et al., “TNFA—308 (rs1800629) polymorphism is asso-
ciated with a higher risk of cardiovascular disease in patients
with rheumatoid arthritis,” Atherosclerosis, vol. 216, no. 1, pp.
125–130, 2011.
[16] R. Lo´pez-Mej´ıas, M. Garc´ıa-Bermu´dez, C. Gonza´lez-Juanatey
et al., “NFKB1-94ATTG ins/del polymorphism (rs28362491) is
associated with cardiovascular disease in patients with rheuma-
toid arthritis,” Atherosclerosis, vol. 224, no. 2, pp. 426–429, 2012.
[17] R. Lo´pez-Mej´ıas, C. Gonza´lez-Juanatey, M. Garc´ıa-Bermu´dez
et al., “The lp13.3 genomic region -rs599839- is associated with
endothelial dysfunction in patients with rheumatoid arthritis,”
Arthritis Research &Therapy, vol. 14, no. 2, p. R42, 2012.
[18] L. L. Bausserman, A. L. Saritelli, and D. Milosavljevic, “High-
density lipoprotein subfractions measured in stored serum,”
Clinical Chemistry, vol. 40, no. 9, pp. 1713–1716, 1994.
[19] P. N. M. Demacker, A. G. M. Hijmans, D. F. van Sommeren-
Zondag, and A. P. Jansen, “Stability of frozen liquid control
sera for assay of cholesterol in high-density lipoprotein,”Clinical
Chemistry, vol. 28, no. 1, pp. 155–157, 1982.
[20] M. N. Nanjee and N. E. Miller, “Evaluation of long-term frozen
storage of plasma for measurement of high-density lipoprotein
and its subfractions by precipitation,”Clinical Chemistry, vol. 36,
no. 5, pp. 783–788, 1990.
[21] J. P. Reckless, D. J. Betterridge, P.Wu, B. Payne, and D. J. Galton,
“Effect of storage on plasma-lipoproteins,” The Lancet, vol. 2,
article 350, 1977.
[22] J. D. Curb, M. L. Overturf, and R. B. Harrist, “Lability of HDL-
cholesterol during serum storage,” Atherosclerosis, vol. 37, no. 4,
pp. 641–645, 1980.
[23] P. S. Bachorik, R. E.Walker, and P. O. Kwiterovich Jr., “Determi-
nation of high density lipoprotein-cholesterol in human plasma
stored at -70∘C,” Journal of Lipid Research, vol. 23, no. 8, pp.
1236–1242, 1982.
[24] Y. M. Stokes, C. E. Salmond, L. M. Carpenter, and T. J.
Welby, “Stability of total cholesterol, high-density-lipoprotein
cholesterol, and triglycerides in frozen sera,”Clinical Chemistry,
vol. 32, no. 6, pp. 995–999, 1986.
[25] H. G. M. Tiedink and M. B. Katan, “Variability in lipoprotein
concentrations in serum after prolonged storage at −20∘C,”
Clinica Chimica Acta, vol. 180, no. 2, pp. 147–156, 1989.
[26] W. J. Shih, P. S. Bachorik, J. A. Haga, G. L. Myers, and E. A.
Stein, “Estimating the long-term effects of storage at -70∘C on
cholesterol, triglyceride, andHDL-cholesterolmeasurements in
stored sera,”Clinical Chemistry, vol. 46, no. 3, pp. 351–364, 2000.
[27] C. C. Allain, L. S. Poon, C. S. G. Chan, W. Richmond, and P.
C. Fu, “Enzymatic determination of total serum cholesterol,”
Clinical Chemistry, vol. 20, no. 4, pp. 470–475, 1974.
[28] W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation
of the concentration of low-density lipoprotein cholesterol in
plasma, without use of the preparative ultracentrifuge.,”Clinical
Chemistry, vol. 18, no. 6, pp. 499–502, 1972.
[29] J. Perk, G. De Backer, H. Gohlke et al., “European guidelines on
cardiovascular disease prevention in clinical practice (version
2012). The fifth joint task force of the European Society of
Cardiology and Other Societies on cardiovascular disease
prevention in clinical practice (constituted by representatives of
nine societies and by invited experts),” European Heart Journal,
vol. 33, no. 13, pp. 1635–701, 2012.
[30] M. Mogadam, S. W. Ahmed, A. H. Mensch, and I. D. Godwin,
“Within-person fluctuations of serum cholesterol and lipopro-
teins,” Archives of Internal Medicine, vol. 150, no. 8, pp. 1645–
1648, 1990.
[31] S. M. Marcovina, V. P. Gaur, and J. J. Albers, “Biological
variability of cholesterol, triglyceride, low- and high- density
lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-
I and B,” Clinical Chemistry, vol. 40, no. 4, pp. 574–578, 1994.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
